image
Healthcare - Medical - Instruments & Supplies - NYSE - CH
$ 82.98
-1 %
$ 41 B
Market Cap
40.48
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one ALC stock under the worst case scenario is HIDDEN Compared to the current market price of 83 USD, Alcon Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one ALC stock under the base case scenario is HIDDEN Compared to the current market price of 83 USD, Alcon Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one ALC stock under the best case scenario is HIDDEN Compared to the current market price of 83 USD, Alcon Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ALC

image
$98.0$98.0$96.0$96.0$94.0$94.0$92.0$92.0$90.0$90.0$88.0$88.0$86.0$86.0$84.0$84.0$82.0$82.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
9.91 B REVENUE
4.82%
1.41 B OPERATING INCOME
36.00%
1.02 B NET INCOME
-2.08%
2.08 B OPERATING CASH FLOW
40.20%
-1.17 B INVESTING CASH FLOW
-6.67%
-322 M FINANCING CASH FLOW
-52.61%
2.5 B REVENUE
1.96%
395 M OPERATING INCOME
18.98%
223 M NET INCOME
-10.08%
530 M OPERATING CASH FLOW
55.43%
-133 M INVESTING CASH FLOW
38.99%
-171 M FINANCING CASH FLOW
-159.09%
Balance Sheet Alcon Inc.
image
Current Assets 6.31 B
Cash & Short-Term Investments 1.83 B
Receivables 2.08 B
Other Current Assets 2.4 B
Non-Current Assets 24 B
Long-Term Investments 751 M
PP&E 4.84 B
Other Non-Current Assets 18.4 B
6.03 %6.86 %7.90 %15.94 %60.79 %Total Assets$30.3b
Current Liabilities 2.28 B
Accounts Payable 773 M
Short-Term Debt 169 M
Other Current Liabilities 1.34 B
Non-Current Liabilities 6.52 B
Long-Term Debt 4.97 B
Other Non-Current Liabilities 1.55 B
8.79 %15.19 %56.48 %17.61 %Total Liabilities$8.8b
EFFICIENCY
Earnings Waterfall Alcon Inc.
image
Revenue 9.91 B
Cost Of Revenue 4.4 B
Gross Profit 5.51 B
Operating Expenses 4.1 B
Operating Income 1.41 B
Other Expenses 395 M
Net Income 1.02 B
10b10b9b9b8b8b7b7b6b6b5b5b4b4b3b3b2b2b1b1b0010b(4b)6b(4b)1b(395m)1bRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
55.61% GROSS MARGIN
55.61%
14.26% OPERATING MARGIN
14.26%
10.27% NET MARGIN
10.27%
4.72% ROE
4.72%
3.35% ROA
3.35%
4.06% ROIC
4.06%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Alcon Inc.
image
2b2b1b1b1b1b1b1b800m800m600m600m400m400m200m200m0020162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 1.02 B
Depreciation & Amortization 1.23 B
Capital Expenditures -670 M
Stock-Based Compensation 150 M
Change in Working Capital -189 M
Others -440 M
Free Cash Flow 1.41 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Alcon Inc.
image
Wall Street analysts predict an average 1-year price target for ALC of $102 , with forecasts ranging from a low of $85 to a high of $110 .
ALC Lowest Price Target Wall Street Target
85 USD 2.43%
ALC Average Price Target Wall Street Target
102 USD 22.44%
ALC Highest Price Target Wall Street Target
110 USD 32.56%
Price
Max Price Target
Min Price Target
Average Price Target
11011010510510010095959090858580807575May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0.325 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
0.350000.350000.300000.300000.250000.250000.200000.200000.150000.150000.100000.100000.050000.050000.000000.000000.109690.110.2050.210.235740.240.264410.260.325320.332021202120222022202320232024202420252025
Download SVG
Download PNG
Download CSV
5. COMPETITION
slide 2 of 13
6. Ownership
Insider Ownership Alcon Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Alcon Publishes Agenda for 2025 Annual General Meeting GENEVA--(BUSINESS WIRE)--Alcon Publishes Agenda for 2025 Annual General Meeting. businesswire.com - 2 weeks ago
Alcon Publishes Agenda for 2025 Annual General Meeting GENEVA--(BUSINESS WIRE)--Alcon Publishes Agenda for 2025 Annual General Meeting. businesswire.com - 2 weeks ago
ALC Stock May Rise With the Introduction of PanOptix Pro in US Alcon introduces Clareon PanOptix Pro IOL to select practices across the United States, with commercial availability expected in May. zacks.com - 2 weeks ago
Alcon Expands Leadership in IOL Innovation with Clareon PanOptix Pro, Delivering Best-in-Class Light Utilization and Less Light Scatter GENEVA--(BUSINESS WIRE)--Alcon Expands Leadership in IOL Innovation with Clareon PanOptix Pro, Delivering Best-in-Class Light Utilization and Less Light Scatter. businesswire.com - 2 weeks ago
3 Stocks to Watch in the Evolving Cell-Based Ophthalmic Therapy Space ALC, GKOS and REGN are well-positioned to benefit from the evolving space of cell-based ophthalmic therapy. zacks.com - 2 weeks ago
Alcon (ALC) Soars 6.0%: Is Further Upside Left in the Stock? Alcon (ALC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. zacks.com - 3 weeks ago
LENSAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LENSAR, Inc. - LNSR NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of LENSAR, Inc. (NasdaqCM: LNSR) to Alcon Inc. (NYSE: ALC). Under the terms of the proposed transaction, shareholders of LENSAR will receive $14.00 in cash, with an additional non-tradeable contingent value right offering up to $2.75 per share in cash conditioned on achievement of a milestone, for each. businesswire.com - 3 weeks ago
Alcon Stock Might Rise as Clareon Vivity IOL Secures CE Mark Approval ALC secures CE Mark for Clareon Vivity IOL, bringing advanced presbyopia-correcting lens technology to Europe, enhancing visual outcomes with cutting-edge innovation. zacks.com - 3 weeks ago
ALC Stock Rises Following the Merger Agreement With LENSAR Alcon enters into a definitive merger agreement to acquire LENSAR's ALLY Robotic Cataract Laser Treatment System, proprietary Streamline software technology and LENSAR legacy laser system. zacks.com - 3 weeks ago
Alcon Announces CE Mark Approval and Commercialization of Clareon Vivity IOL in Europe, Expanding Visual Possibilities GENEVA--(BUSINESS WIRE)--Alcon Announces CE Mark Approval and Commercialization of Clareon Vivity IOL in Europe, Expanding Visual Possibilities. businesswire.com - 3 weeks ago
Alcon Agrees to Acquire LENSAR, Inc. GENEVA, Switzerland & ORLANDO, Fla.--(BUSINESS WIRE)--Alcon Agrees to Acquire LENSAR, Inc. businesswire.com - 3 weeks ago
Retinal Surgery Devices Market Outlook Report 2025-2033: Revenues Set to Double, Reaching $4.83 Billion by 2033, Led by Topcon Corp., Alcon, and Carl Zeiss Dublin, March 24, 2025 (GLOBE NEWSWIRE) -- The "Retinal Surgery Devices Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" has been added to ResearchAndMarkets.com's offering. The Retinal Surgery Devices Market is expected to reach US$ 4.84 billion in 2033 from US$ 2.48 billion in 2024, with a CAGR of 7.71% from 2025 to 2033. Some of the main reasons propelling the market include the rising prevalence of a number of eye ailments, increased awareness of eye issues and available treatments, and the expanding use of minimally invasive (MI) surgical technology. Rising prevalence of retinal diseases The market for retinal surgery instruments is mostly driven by the increasing incidence of retinal disorders. Age-related macular degeneration (AMD), diabetic retinopathy, and retinal detachment are among the conditions that are growing increasingly prevalent, especially as the world's population ages and the prevalence of diabetes rises. The need for sophisticated retinal surgery equipment, including lasers, vitrectomy tools, and surgical microscopes, is increasing since these conditions frequently call for surgical intervention. The demand for specialist surgical instruments is boosted by more surgeries performed as a result of early diagnosis and greater awareness of these disorders. Market growth and innovation in the industry are still being propelled by this trend. Around 2.2 billion people worldwide suffer from near or distant vision impairment, of which nearly 1 billion cases may have been avoided, according to a WHO report published in October 2021. It demonstrates the high prevalence of visual impairment patients globally as well as the potential for therapy. Because of this, the demand for ophthalmic medications is quite high, which will favorably affect the market's growth over the study's projected period. Increasing Geriatric Population One major factor propelling the market for retinal surgery instruments is the aging population. People are more vulnerable to age-related retinal disorders include diabetic retinopathy, macular degeneration, and retinal detachment as they get older. By 2050, there will be about 2 billion people worldwide who are 60 years of age or older, up from 900 million in 2015, according to figures from the World Health Organization (WHO) in 2021. Approximately 125 million people are 80 years of age or older at the moment. globenewswire.com - 3 weeks ago
8. Profile Summary

Alcon Inc. ALC

image
COUNTRY CH
INDUSTRY Medical - Instruments & Supplies
MARKET CAP $ 41 B
Dividend Yield 0.00%
Description Alcon Inc., an eye care company, researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for use in surgical procedures. Its cataract products include centurion vision system, LenSx femtosecond laser, LuxOR surgical ophthalmic microscope, NGENUITY 3D visualization system, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantables products, including AcrySof IQ IOLs products include monofocal IOLs and advanced technology IOLs under the PanOptix and ReSTOR brands for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, glaucoma, contact lens care, and ocular allergies; and ocular vitamins and redness relievers under the TOTAL, PRECISION, DAILIES AquaComfort PLUS, Air Optix, Opti-Free, Clear Care, Tears Naturale, Genteal, ICAPS, and Vitalux brands. The company was formerly known as Alcon Universal S.A. and changed the name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
Contact Chemin de Blandonnet 8, Geneva, 1214 https://www.alcon.com
IPO Date April 9, 2019
Employees 25599
Officers Mr. Laurent Attias SVice President of Corporate Strategy, Business Development and Licensing (BD&L), M&A Mr. David J. Endicott Chief Executive Officer & Director Mr. Muru Murugappan Senior Vice President and Chief Information & Transformation Officer Ms. Kimberly Martin Senior Vice President, Chief HR Officer & Corporate Communications Mr. Royce R. Bedward J.D. Senior Vice President, General Counsel & Corporate Secretary Mr. Timothy C. Stonesifer Senior Vice President & Chief Financial Officer Mr. Ian Bell Senior Vice President & Chief Operating Officer Margaret Buckley Chief Accounting Officer Mr. Leon Sergio Duplan Fraustro Senior Vice President & President of Americas Dr. Franck Leveiller SVice President of Global Research & Development and Chief Scientific Officer